Aptinyx
Evanston
Illinois
United States
66 articles with Aptinyx
-
Shares of Illinois-based Aptinyx Inc. have plunged more than 67 percent in premarket trading after the company announced its mid-stage treatment for painful diabetic peripheral neuropathy failed to show statistical significance.
-
Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy
11/1/2018
Top-line Data Expected Early in the First Quarter of 2019
-
Depression Awareness Month: Ketamine Clinics Put Not-Always Flattering Spotlight on Treatment
10/15/2018
Depression affects almost 20 million Americans yearly and major depressive disorders affect nearly 300 million people worldwide. The annual market for these disorders is approximately $83 billion. -
Aptinyx Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
6/25/2018
Aptinyx Inc. announced the closing of its initial public offering of 7,359,998 shares of common stock at a public offering price of $16.00 per share
-
Autolus Brings in $150 Million in IPO, Continues Strong Investment Trend for Biotechs This Week
6/22/2018
Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month. -
It’s a super-busy week for biotech initial public offerings (IPOs) with six companies raking in a total of around $568 million.
-
Aptinyx Announces Pricing of Initial Public Offering
6/21/2018
Pricing of its initial public offering of 6,399,999 shares of its common stock at a public offering price of $16.00 per share.
-
Axial Biotherapeutics Announces Neurology Scientific and Clinical Advisory Board
6/12/2018
Axial Biotherapeutics today announced the appointment of renowned researchers and thought leaders with expertise in neurology, Parkinson’s disease and regulatory strategy to its scientific and clinical advisory board.
-
Six Biotechs Launch IPO Plans in Last Days of May, While Iterum Therapeutics Adjusts IPO Goals
5/29/2018
It’s been a busy month for IPOs. Numerous biotech companies announced their intentions to publicly list their stock on an exchange in the U.S. or abroad in order to gain new funding to advance developmental programs. -
A day after Illinois-based Aptinyx strengthened its relationship with pharma giant Allergan, the company is now eying an $80 million initial public offering of stock on the Nasdaq Exchange.
-
Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration
5/22/2018
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small-molecule N-methyl-D-aspartate (NMDA) receptor modulator
-
Allergan has exercised an option to acquire an oral small molecule compound from Illinois-based Aptinyx, a spinout of Naurex, Inc., which the Irish company acquired in 2015. The company will use it as a complement to a Phase III depression treatment.
-
Aptinyx Promotes David Houck to Chief Development Officer
5/3/2018
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced that David R. Houck, Ph.D. has been promoted to chief development officer.
-
Aptinyx Presents Data on NMDA Receptor Modulator NYX-458 in a Preclinical Model of Parkinson's Cognitive Impairment at the AAT-AD/PD Focus Meeting 2018
3/15/2018
Aptinyx Inc. announced the presentation of preclinical data that supports advancing the development of a novel N-methyl D-aspartate (NMDA) receptor modulator, NYX-458, as a treatment for cognitive impairment associated with Parkinson's disease.
-
Aptinyx Presents Preclinical and Phase 1 Clinical Data from NYX-2925 at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics
3/8/2018
Aptinyx Inc. announced they will present preclinical and early-stage clinical data from studies of the company's lead product candidate, NYX-2925, at the 20th Annual Meeting of the American Society for Experimental Neurotherapeutics, March 7-10, 2018 in Rockville, MD.
-
Aptinyx Presents NYX-2925 Preclinical Data in Chemotherapy-induced Neuropathic Pain at the American Pain Society Annual Scientific Meeting
3/6/2018
Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced their presentation at the American Pain Society's Annual Scientific Meeting, March 4-6, 2018 in Anaheim, CA.
-
Aptinyx Appoints Ashish Khanna CFO and CBO
2/13/2018
Mr. Khanna has served as chief business officer of Aptinyx since the company's inception in 2015.
-
The round was led by Bain Capital Life Sciences.
-
Aptinyx Granted Fast Track Designation, Initiates Phase I for Second Clinical Candidate, NYX-783, in Post-Traumatic Stress Disorder
12/7/2017
The U.S. Food and Drug Administration has granted Aptinyx Fast Track designation for the development of NYX-783 for the treatment of PTSD.
-
Aptinyx Bolsters Executive Leadership Team With Appointment of Andy Kidd as CCO
12/7/2017
Andy's experience will be instrumental in achieving and leveraging anticipated milestones,.